"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   ...   6   7   8   9   10   Next >  Last >> 
  • 15 Oct 2015 7:11 PM | Anonymous

    The U.S. Food and Drug Administration granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors. Read more. 

<< First  < Prev   ...   6   7   8   9   10   Next >  Last >> 

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software